Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash from Operations (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Cash from Operations for 15 consecutive years, with 1493000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 167.68% year-over-year to 1493000.0, compared with a TTM value of 7985000.0 through Sep 2025, down 133.84%, and an annual FY2024 reading of 26980000.0, up 257.38% over the prior year.
  • Cash from Operations was 1493000.0 for Q3 2025 at Fennec Pharmaceuticals, up from 3686000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 39047000.0 in Q1 2024 and bottomed at 8387000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 1338294.12, with a median of 3686000.0 recorded in 2025.
  • Peak annual rise in Cash from Operations hit 800.14% in 2024, while the deepest fall reached 112.54% in 2024.
  • Year by year, Cash from Operations stood at 4426000.0 in 2021, then plummeted by 53.68% to 6802000.0 in 2022, then increased by 28.55% to 4860000.0 in 2023, then skyrocketed by 69.67% to 1474000.0 in 2024, then soared by 201.29% to 1493000.0 in 2025.
  • Business Quant data shows Cash from Operations for FENC at 1493000.0 in Q3 2025, 3686000.0 in Q2 2025, and 4318000.0 in Q1 2025.